These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 11329288

  • 1. Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase.
    McLean JE, Neidhardt EA, Grossman TH, Hedstrom L.
    Biochemistry; 2001 Feb 20; 40(7):2194-200. PubMed ID: 11329288
    [Abstract] [Full Text] [Related]

  • 2. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
    Knecht W, Löffler M.
    Biochem Pharmacol; 1998 Nov 01; 56(9):1259-64. PubMed ID: 9802339
    [Abstract] [Full Text] [Related]

  • 3. Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity.
    Baldwin J, Farajallah AM, Malmquist NA, Rathod PK, Phillips MA.
    J Biol Chem; 2002 Nov 01; 277(44):41827-34. PubMed ID: 12189151
    [Abstract] [Full Text] [Related]

  • 4. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.
    Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA.
    Biochemistry; 1996 Jan 30; 35(4):1270-3. PubMed ID: 8573583
    [Abstract] [Full Text] [Related]

  • 5. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide.
    Bruneau JM, Yea CM, Spinella-Jaegle S, Fudali C, Woodward K, Robson PA, Sautès C, Westwood R, Kuo EA, Williamson RA, Ruuth E.
    Biochem J; 1998 Dec 01; 336 ( Pt 2)(Pt 2):299-303. PubMed ID: 9820804
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.
    Knecht W, Henseling J, Löffler M.
    Chem Biol Interact; 2000 Jan 03; 124(1):61-76. PubMed ID: 10658902
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.
    Chen SF, Perrella FW, Behrens DL, Papp LM.
    Cancer Res; 1992 Jul 01; 52(13):3521-7. PubMed ID: 1617622
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression.
    Neidhardt EA, Punreddy SR, McLean JE, Hedstrom L, Grossman TH.
    J Mol Microbiol Biotechnol; 1999 Aug 01; 1(1):183-8. PubMed ID: 10941801
    [Abstract] [Full Text] [Related]

  • 13. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice.
    Xu X, Blinder L, Shen J, Gong H, Finnegan A, Williams JW, Chong AS.
    J Immunol; 1997 Jul 01; 159(1):167-74. PubMed ID: 9200452
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of canine distemper virus replication by blocking pyrimidine nucleotide synthesis with A77 1726, the active metabolite of the anti-inflammatory drug leflunomide.
    Li Y, Yi L, Cheng S, Wang Y, Wang J, Sun J, Zhang Q, Xu X.
    J Gen Virol; 2021 Mar 01; 102(3):. PubMed ID: 33416466
    [Abstract] [Full Text] [Related]

  • 15. Structural and functional comparison of agents interfering with dihydroorotate, succinate and NADH oxidation of rat liver mitochondria.
    Jöckel J, Wendt B, Löffler M.
    Biochem Pharmacol; 1998 Oct 15; 56(8):1053-60. PubMed ID: 9776318
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Synthesis of beta-hydroxy-propenamide derivatives and the inhibition of human dihydroorotate dehydrogenase.
    Kim TH, Na HS, Löffler M.
    Arch Pharm Res; 2003 Mar 15; 26(3):197-201. PubMed ID: 12723931
    [Abstract] [Full Text] [Related]

  • 18. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound.
    Williamson RA, Yea CM, Robson PA, Curnock AP, Gadher S, Hambleton AB, Woodward K, Bruneau JM, Hambleton P, Moss D, Thomson TA, Spinella-Jaegle S, Morand P, Courtin O, Sautés C, Westwood R, Hercend T, Kuo EA, Ruuth E.
    J Biol Chem; 1995 Sep 22; 270(38):22467-72. PubMed ID: 7673235
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
    Greene S, Watanabe K, Braatz-Trulson J, Lou L.
    Biochem Pharmacol; 1995 Sep 07; 50(6):861-7. PubMed ID: 7575649
    [Abstract] [Full Text] [Related]

  • 20. A second dihydroorotate dehydrogenase (Type A) of the human pathogen Enterococcus faecalis: expression, purification, and steady-state kinetic mechanism.
    Marcinkeviciene J, Jiang W, Locke G, Kopcho LM, Rogers MJ, Copeland RA.
    Arch Biochem Biophys; 2000 May 01; 377(1):178-86. PubMed ID: 10775458
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.